| abstract |
The invention relates to a new category of immunosuppressive compounds having an affinity for the binding protein of FK-506 (FKBP). Once binding to said protein, the immunosuppressive compounds inhibit the activity of prolyl cis-trans isomerase (rotamase) of FKBP, as well as the activation of T lymphocytes. The compounds described by the invention, as immunosuppressive drugs, for the purpose of preventing or considerably reducing rejection in bone marrow transplants and organ transplants, as well as in the treatment of numerous autoimmune diseases in humans and other mammals . |